Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Dovitinib (TKI258) in Castration-Resistant Prostate Cancer
NCT01741116Phase 2Completed
- Sponsor
- Korean Cancer Study Group
- Start
- Nov 2012
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dovitinib in castration-resistant prostate cancer (CRPC), sponsored by Korean Cancer Study Group. Started Nov 2012; status: completed.
02
Drugs
dovitinib
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT01741116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01741116.